標(biāo)題: Titlebook: Clinical Applications of Botulinum Neurotoxin; Keith A. Foster Book 2014 Springer Science+Business Media New York 2014 botox.botulism.dysp [打印本頁] 作者: MAXIM 時間: 2025-3-21 18:42
書目名稱Clinical Applications of Botulinum Neurotoxin影響因子(影響力)
書目名稱Clinical Applications of Botulinum Neurotoxin影響因子(影響力)學(xué)科排名
書目名稱Clinical Applications of Botulinum Neurotoxin網(wǎng)絡(luò)公開度
書目名稱Clinical Applications of Botulinum Neurotoxin網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Clinical Applications of Botulinum Neurotoxin被引頻次
書目名稱Clinical Applications of Botulinum Neurotoxin被引頻次學(xué)科排名
書目名稱Clinical Applications of Botulinum Neurotoxin年度引用
書目名稱Clinical Applications of Botulinum Neurotoxin年度引用學(xué)科排名
書目名稱Clinical Applications of Botulinum Neurotoxin讀者反饋
書目名稱Clinical Applications of Botulinum Neurotoxin讀者反饋學(xué)科排名
作者: 合并 時間: 2025-3-21 22:30
Current Topics in Neurotoxicityhttp://image.papertrans.cn/c/image/227741.jpg作者: GROUP 時間: 2025-3-22 03:38 作者: 周年紀(jì)念日 時間: 2025-3-22 06:58 作者: Progesterone 時間: 2025-3-22 11:15 作者: 美食家 時間: 2025-3-22 14:54
Future Developments: Engineering the Neurotoxin, the neurotoxins and neurotoxin domains. These opportunities and the status of their development are reviewed in this chapter, which brings together the findings detailed in the companion volume to this book, KA Foster (ed) ., Springer, New York, and shows how they can be applied for the development of innovative therapeutics and research tools.作者: 美食家 時間: 2025-3-22 18:24 作者: 攤位 時間: 2025-3-23 00:29 作者: Pelago 時間: 2025-3-23 04:12 作者: strdulate 時間: 2025-3-23 09:23
Environmental Risk and Sustainability,clinical utility in treating conditions involving hyperactivity of the autonomic nervous system, including hyperhidrosis, hypersalivation and conditions of smooth muscle hyperactivity. These clinical uses of the neurotoxin are reviewed in this chapter.作者: Expiration 時間: 2025-3-23 12:20 作者: 紅腫 時間: 2025-3-23 16:06
Grundlagen und Forschungsdesign,tonin-gene-related peptide) and pro-inflammatory agents (prostaglandins, bradykinin, histamine) from peripheral nerve endings and sensory ganglia and reduce the phenomena of peripheral and central sensitization, major factors for pain chronicity. A review of class I and II studies (double blind, pla作者: cumber 時間: 2025-3-23 20:14
https://doi.org/10.1007/978-3-031-19600-3 the neurotoxins and neurotoxin domains. These opportunities and the status of their development are reviewed in this chapter, which brings together the findings detailed in the companion volume to this book, KA Foster (ed) ., Springer, New York, and shows how they can be applied for the development作者: Initial 時間: 2025-3-23 23:10 作者: 連接 時間: 2025-3-24 04:02 作者: 開玩笑 時間: 2025-3-24 08:07 作者: CONE 時間: 2025-3-24 14:06 作者: 阻擋 時間: 2025-3-24 17:33
Book 2014s. This volume fully evaluates the status of neurotoxin research and exploitation. The book is a multi-authored collection of chapters written by the leading authorities responsible for the current scientific and clinical research that is advancing the understanding and exploitation of the neurotoxins and is both up to date and authoritative.作者: auxiliary 時間: 2025-3-24 20:39 作者: 留戀 時間: 2025-3-24 23:19 作者: 健談 時間: 2025-3-25 03:59
Fearing ‘Frankenfoods’: Emergence of ,gent of benefit in an ever-expanding range of diseases of neuronal hyperactivity. Establishing the structural basis of its activity has opened up opportunities to engineer the toxin to create novel proteins of increased therapeutic effect and potential.作者: craving 時間: 2025-3-25 09:37
Grundlagen und Forschungsdesign,ciceptive effect as therapeutic benefit has also been shown in painful bladder conditions such as interstitial cystitis (IC). Outcomes in the pediatric population are encouraging, and serious adverse events after BoNT-A injection are infrequent.作者: 皺痕 時間: 2025-3-25 14:21
Overview and History of Botulinum Neurotoxin Clinical Exploitation,gent of benefit in an ever-expanding range of diseases of neuronal hyperactivity. Establishing the structural basis of its activity has opened up opportunities to engineer the toxin to create novel proteins of increased therapeutic effect and potential.作者: 我吃花盤旋 時間: 2025-3-25 16:56 作者: 尖 時間: 2025-3-25 21:14 作者: 抱怨 時間: 2025-3-26 01:46 作者: LATE 時間: 2025-3-26 08:19
Risk Science and Sustainability range of disorders of muscle hyper-contraction. Botulinum neurotoxin is now a major clinical product for the treatment of spasticity and muscle hyperactivity. Muscle relaxation also underpins the cosmetic use of the neurotoxin. This chapter will review and assess the clinical utility of the various botulinum products in neuromuscular disorders.作者: 責(zé)問 時間: 2025-3-26 09:14
Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders, range of disorders of muscle hyper-contraction. Botulinum neurotoxin is now a major clinical product for the treatment of spasticity and muscle hyperactivity. Muscle relaxation also underpins the cosmetic use of the neurotoxin. This chapter will review and assess the clinical utility of the various botulinum products in neuromuscular disorders.作者: 文字 時間: 2025-3-26 13:27 作者: Needlework 時間: 2025-3-26 18:02 作者: 褪色 時間: 2025-3-26 22:15
Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders,on and relaxation of the muscle with a duration of several months. This initial application has been followed by use of the neurotoxin to treat a wide range of disorders of muscle hyper-contraction. Botulinum neurotoxin is now a major clinical product for the treatment of spasticity and muscle hyper作者: 釘牢 時間: 2025-3-27 04:11
Clinical Use of Botulinum Neurotoxin: Autonomic Conditions,clinical utility in treating conditions involving hyperactivity of the autonomic nervous system, including hyperhidrosis, hypersalivation and conditions of smooth muscle hyperactivity. These clinical uses of the neurotoxin are reviewed in this chapter.作者: Alpha-Cells 時間: 2025-3-27 06:21
Clinical Use of Botulinum Neurotoxin: Urogenital Disorders Including Overactive Bladder,ine (ACh) release at the presynaptic cholinergic neuromuscular junction and induces a flaccid paralysis. This impact on the bladder has made BoNT-A an attractive therapeutic option for detrusor overactivity (DO) due to neurogenic and idiopathic reasons that are refractory to traditional treatment wi作者: 巨碩 時間: 2025-3-27 10:11 作者: urethritis 時間: 2025-3-27 14:04 作者: 流浪者 時間: 2025-3-27 20:41 作者: Interregnum 時間: 2025-3-27 23:27
Grundlagen und Forschungsdesign,ly effective) for postherpetic and posttraumatic neuralgia, pain of plantar fasciitis, piriformis syndrome and pain in total knee arthroplasty. Level C evidence (one class II study—possibly effective) denotes allodynia of diabetic neuropathy, chronic low back pain, painful knee osteoarthritis, anter作者: 打折 時間: 2025-3-28 04:37
Book 20093rd editione zur Verfügung. Um seine Aufgaben ordnungsgem?? erfüllen und seine Handlungsspielr?ume effektiv nutzen zu k?nnen, ist für den Gesch?ftsführer die Kenntnis der rechtlichen Rahmenbedingungen unerl?sslich. Auch ist er daran interessiert, seine haftungsrechtlichen Risiken zu erkennen und zu minimieren.
